1 median OS was not reached after 57 months of
median follow-up).
2 re 0.8% and 6.5% respectively, with 26-month
median follow up.
3 for baseline characteristics during 6 years'
median follow-up.
4 In HD11 (N = 1,395;
median follow-up,
106 months), superiority of bleomycin,
5 data were reported by general practitioners (
median follow-up 14.8 y).
6 In HD8 (N = 1,064;
median follow-up,
153 months), noninferiority of involve
7 ith minimal comorbidities or no comorbidity (
median follow-up,
16.49 months).
8 rvival rates were 60% and 85%, respectively (
median follow-up,
16.9 months).
9 s [HIV] positive) pre- and post-DAA therapy (
median follow-up 28 months).
10 4 patients (12.9%) met the primary endpoint (
median follow-up 3.9 years; interquartile range: 2.0 to
11 dinal with repeated serum sampling (n = 246,
median follow-up =
3.1 years, interquartile range [IQR]
12 infected and 377 HIV-uninfected individuals (
median follow-up =
3.9/4.1 years, respectively) included
13 Among 26,577 patients with cirrhosis (
median follow-up =
4.7 years), the mean PTUDS was 17.8 +
14 % (+/-6%) and 77.7% (+/-6.2%), respectively (
median follow-up 41 months).
15 urviving) of 88% and a 5.9% risk of relapse (
median follow-up 49 [6-136] months).
16 seventy-three patients (age, 0.1-22.7 years;
median follow-up,
58 months) were included.
17 ntal Ca with 400 IU vitamin D3/d or placebo (
median follow-up:
6.5 y).
18 All patients are alive at
median follow-up 7.4 years (range, 2.7 to 10 years).
19 fects were sustained for an extended period (
median follow-up 9.2 weeks [IQR 6.4-13.4]) in the PENFS
20 In HD10 (N = 1,190;
median follow-up,
98 months), noninferiority of two cycl
21 Median follow up after IRA was 10.6 years.
22 In total, 99 of 146 received SRT with a
median follow-up after radiation treatment of 10.5 mo (i
23 The
median follow-up after the diagnosis of metastases was 7
24 Median follow-up after transplantation was 6.6 years (37
25 outcomes were evaluated during the 2.8 years
median follow-up and compared by AF pattern.
26 Median follow-up at the end of the trial on Nov 5, 2014,
27 he second interim overall survival analysis (
median follow-up duration 24.1 months [IQR 19.5-26.1]).
28 come occurred in 331 patients (33.7%) over a
median follow-up duration of 2.8 years (interquartile ra
29 Results With a
median follow-up duration of 6.5 years, 5-year overall s
30 At the data cutoff,
median follow-up duration was 11.0 months (range, 1.3 to
31 s 185 (interquartile range, 75-305), and the
median follow-up duration was 180 days (interquartile ra
32 Median follow-up for all patients was 18.6 months.
33 Median time to recurrence was 14 months, and
median follow-up for control subjects was 102 months.
34 Median follow-up for overall survival was 7.00 months (I
35 The
median follow-up for patients last known to be alive was
36 Median follow-up for patients with adenocarcinoma was 27
37 Median follow-up for surviving patients was 32.5 months
38 Median follow-up for surviving patients was 47 months.
39 Median follow-up for surviving patients was 8.8 years.
40 The
median follow-up for the 80 patients was 6.9 years and t
41 nts were followed from 1985 to 2009, and the
median follow-up from baseline to CRC diagnosis was 8.2
42 The
median follow-up from date of disengagement to 30 June 2
43 The
median follow-up (
n = 405) was 9.1 years (interquartile
44 With a
median follow up of 25.7 months, median progression-free
45 After a
median follow-up of 1.32 years (interquartile range, 0.5
46 Over a
median follow-up of 1.5 years, 11.6% of patients receive
47 During a
median follow-up of 10 months, the ECG remained normal e
48 After a
median follow-up of 10 years, 45% of 21,140 men and 45%
49 After a
median follow-up of 10.9 years and 8.6 years, respective
50 After a
median follow-up of 11 years (IQR 10.09-11.53), random a
51 During a
median follow-up of 11 years, 149 (12%) participants wer
52 nts, from 4465 patients who continued with a
median follow-up of 11.1 months in 2 OLE trials.
53 During a
median follow-up of 11.1 years, we identified 384 incide
54 After a
median follow-up of 12 months (interquartile range: 7-16
55 At a
median follow-up of 12.0 months (IQR 8.6-18.0), 23 (31.1
56 After a
median follow-up of 13 years, 1 or more ODHs were detect
57 At a
median follow-up of 13.9 months, best overall response w
58 2 patients, and no change in 1 patient with
median follow-up of 135 days (range, 84 to 1,005 days).
59 re death from cardiovascular causes during a
median follow-up of 15 months and a hierarchical composi
60 At a
median follow-up of 15.2 months, 100 (81%) patients achi
61 At
median follow-up of 15.6 months, progression-free surviv
62 matological and immunological phenotype at a
median follow-up of 18 months (range, 5 months to 13 yea
63 At the latest
median follow-up of 19 months, there was 100% (death-cen
64 as), we obtained 1249 echocardiograms over a
median follow-up of 2.0 (interquartile range, 1.0-3.0) y
65 atin users and 3490 [35%] non-users), with a
median follow-up of 2.3 years (2.2-2.4).
66 Among HF cases, 952 deaths occurred over a
median follow-up of 2.3 years.
67 Over a
median follow-up of 2.4 years (25th, 75th percentiles, 1
68 who did not receive LRT, the dropout rate at
median follow-up of 2.4 years and the progression rate t
69 Over a
median follow-up of 2.4 years, the primary composite out
70 Two hundred ninety-seven eyes with a
median follow-up of 2.6 years were included.
71 Over a
median follow-up of 2.6 years, AF was associated with a
72 During a
median follow-up of 2.7 years (IQR, 1.5-4.6 years) in th
73 r and 11,811 died from other causes during a
median follow-up of 2.8 years (interquartile range, 1.3
74 At a
median follow-up of 2.8 years (range, 0.03-12.8 years),
75 At a
median follow-up of 2.8 years, the estimated 3-year rate
76 During the
median follow-up of 2.9 years, 254 (24%) patients develo
77 With a
median follow-up of 20 months, the overall median event-
78 Results After a
median follow-up of 20.7 years (range, 5.0 to 49.8 years
79 At a
median follow-up of 20.8 months (range, 5 month-3.3 year
80 After a
median follow-up of 21 years, 592 (5.6%) participants ha
81 At a
median follow-up of 22 months, the estimated cumulative
82 At a
median follow-up of 22.9 months (95% CI 18.4-26.1), the
83 During a
median follow-up of 23.6 years, a total of 346 cases of
84 After a
median follow-up of 24 (15-43) months, 20 (20%) patients
85 After a
median follow-up of 24 months (range, 10 approximately 3
86 Over a
median follow-up of 24.6 years, 256 kidney failure event
87 At database lock on July 15, 2015, at a
median follow-up of 24.9 months (IQR 24.3 to not attaina
88 At a
median follow-up of 25 months (IQR 12-56), 556 lenalidom
89 nt; 19 patients were still in treatment at a
median follow-up of 25 months.
90 , or unstable angina hospitalizations over a
median follow-up of 26.1 months.
91 During a
median follow-up of 27 months (IQR: 6 to 62 months), 50%
92 n-label, single-group assignment study, with
median follow-up of 27.3 months for all patients and 79.
93 Sustained remissions were achieved, and at a
median follow-up of 28.6 months, 86% of patients with di
94 terizations for attempted Melody TPVR with a
median follow-up of 3 years (1 day to 9.1 years).
95 the 89 (81%) patients were included after a
median follow-up of 3.0 (0.9-4.7) years.
96 During a
median follow-up of 3.2 years, clinical ischemic stroke
97 and 5079 [50%] in the placebo group), with a
median follow-up of 3.3 years (IQR 2.7-3.7).
98 With a
median follow-up of 3.3 years, the late (31-day to 5-yea
99 om had a cardiovascular disease event during
median follow-up of 3.7 years (IQR 2.7-4.8).
100 ask hours/week and adverse outcomes during a
median follow-up of 3.7 years were evaluated.
101 During
median follow-up of 3.7 years, compared with placebo, ca
102 During a
median follow-up of 3.7 years, there were 591 cases of C
103 ere compared between treatment arms during a
median follow-up of 3.81 years.
104 ata cutoff, 92 patients (87.6%) had CR, with
median follow-up of 30 months from first CR.
105 With a
median follow-up of 31.5 months (IQR 18.9-50.8), there w
106 After a
median follow-up of 32 months, there were no grade 3 tox
107 MACE occurred in 31% of subjects during a
median follow-up of 32 months.
108 t was reached in 188 patients (40%) during a
median follow-up of 325 days (interquartile range: 85 to
109 A previous analysis with a
median follow-up of 34 months showed a superior 3-year t
110 With
median follow-up of 34 months, 15 of 84 evaluable patien
111 Results After a
median follow-up of 34 months, with 25% (R-CHOP) and 18%
112 d primary malignancies for lenalidomide at a
median follow-up of 34 months.
113 At a
median follow-up of 34.9 months in arm A and arm B, medi
114 At a
median follow-up of 36 months, the study reveals no diff
115 With a
median follow-up of 37 months (IQR 30-44), the estimated
116 At a
median follow-up of 370 days, the 1-year progression-fre
117 Over a
median follow-up of 4.0 years, 340 participants died.
118 terization, and 6-minute walk testing with a
median follow-up of 4.0 years.
119 During a
median follow-up of 4.1 years, 423 patients reached the
120 cidents of MS (16.1%) were observed during a
median follow-up of 4.5 years.
121 At a
median follow-up of 4.51 years, there were 20 deaths (35
122 At a
median follow-up of 4.7 years (interquartile range [IQR]
123 Over a
median follow-up of 4.8 years, there were 225 acute coro
124 nts were observed in 319 participants over a
median follow-up of 4.8 years.
125 ents reached the combined end point during a
median follow-up of 4.8 years.
126 At a
median follow-up of 4.96 years for the 267 patients eval
127 Over a
median follow-up of 40 months, the Rtx group had signifi
128 After a
median follow-up of 40.6 months, the event-free survival
129 pectively; P=0.42 by the log-rank test) at a
median follow-up of 43 months.
130 ated patients, 105 (16.0%) achieved CR after
median follow-up of 43 months.
131 At a
median follow-up of 45 months (IQR 35-58), median overal
132 Over a
median follow-up of 46 months, 113 of 1411 patients who
133 With a
median follow-up of 46 months, the PFS of panitumumab pl
134 erwent a laparoscopic Linx implant and had a
median follow-up of 48 months [interquartile range (IQR)
135 After a
median follow-up of 49 months, 6 patients died, 2 develo
136 With a
median follow-up of 49.5 months, 5 of 107 patients exper
137 Over a
median follow-up of 5 years, we observed 70 ESRD events
138 During a
median follow-up of 5.0 years (interquartile range, 3.5-
139 vival (log-rank P=0.04) after STEMI during a
median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier
140 After a
median follow-up of 5.2 years (IQR 2.1-5.3), patients in
141 y 1, 1985, through December 31, 2011, with a
median follow-up of 5.2 years until death, were used in
142 ongitudinal cohort of 678 stable RTRs with a
median follow-up of 5.3 y (IQR: 4.8-6.1 y) and 297 healt
143 With a
median follow-up of 5.3 years (range, 0.6 to 9.9 years),
144 identified, of whom 613 (60%) recurred at a
median follow-up of 50 months.
145 all survival) follow-up were compared over a
median follow-up of 50.5 (+/-3.7) months for DCD and 66.
146 With longer
median follow-up of 52 months (October 2016), overall su
147 of disease recurrence were observed after a
median follow-up of 54 months.
148 nderwent a complete resection of CLM, with a
median follow-up of 55 months.
149 Overall mortality was 38% with a
median follow-up of 55 months.
150 , telmisartan, and their combination, with a
median follow-up of 56 months.
151 Over a
median follow-up of 6.7 (IQR: 3.9 to 9.8) years, 556 (92
152 During a
median follow-up of 6.8 years, 256 recipients died, 35 (
153 (median age 61.3 years, 55.2% women) with a
median follow-up of 6.9 years, 123 participants develope
154 After a
median follow-up of 60 months (IQR 53-72), disease-free
155 of incident HF hospitalization or death at a
median follow-up of 608 days.
156 vived (estimated survival 57 +/- 13%) with a
median follow-up of 65 months (minimum 38 months).
157 It included 1437846 patients with a
median follow-up of 65 months.
158 45-63) years and 2521 deaths (4.2%) during a
median follow-up of 7 (IQR, 4.1-9.6) years.
159 rt a post hoc analysis of this trial after a
median follow-up of 7 years.
160 During a
median follow-up of 7.1 years, there were 2636 total HF
161 included for analysis, 1600 died during the
median follow-up of 7.1 years.
162 Over a
median follow-up of 7.3 years, the rates of hematuria-re
163 Results At a
median follow-up of 7.4 years, addition of rituximab to
164 After a
median follow-up of 7.9 years (IQR 5.6-11.1), 210 colore
165 Median follow-up of 701 eligible patients was 4.1 years
166 With a
median follow-up of 72 months after meningioma diagnosis
167 liver transplantation were included, with a
median follow-up of 73 months.
168 After a
median follow-up of 79 months, 86 patients had discontin
169 After a
median follow-up of 8 (range, 1-41) years in 77 patients
170 Results With a
median follow-up of 8 years for patients in the training
171 mean eGFR was 94 ml/min per 1.73 m(2) Over a
median follow-up of 8 years, 228 (6.4%) cases of inciden
172 vel data) were eligible for analysis, with a
median follow-up of 8 years.
173 8,543 men who were diagnosed with PCa with a
median follow-up of 8.3 years (interquartile range, 5.2
174 After
median follow-up of 8.3 years in 5,469 participants, 322
175 At the data cutoff (Nov 28, 2016) after a
median follow-up of 8.5 months (IQR 5.5-14.0), 44 (58%;
176 Results At a
median follow-up of 8.8 years among eligible participant
177 At a
median follow-up of 84.6 months (IQR 72.0-95.8), MAF sta
178 At a
median follow-up of 85.6 months (IQR 80.6-95.9) no signi
179 During a
median follow-up of 88 months (completed December 31, 20
180 group and 1470 in the no-boost group) with a
median follow-up of 9 years and media boost dose of 14 G
181 At a
median follow-up of 9.3 years (interquartile range, 6.93
182 ctober 8, 1997, to December 31, 2006, with a
median follow-up of 9.3 years, 806 patients with melanom
183 dent coronary events were ascertained over a
median follow-up of 9.3 years.
184 Over a
median follow-up of 9.4 years, 654 diabetes cases were a
185 eat analysis of CALGB (Alliance) 100104 at a
median follow-up of 91 months.
186 umab, and the low incidence of relapse after
median follow-up of approximately 2 years from discontin
187 the per treatment analyses conducted after a
median follow-up of greater than 34 months.
188 Conclusion With a
median follow-up of more than 6 years after treatment di
189 40 patients underwent randomization, and the
median follow-up of the patients was 3.84 years.
190 Median follow-up of the series was 71 months.
191 cirrhosis, 61% (504 of 830) died during the
median follow-up period of 2.26 years.
192 Over a
median follow-up period of 25 months, 1.3% (57 of 4347)
193 After a
median follow-up period of 26 months (interquartile rang
194 During a
median follow-up period of 4.0 years, it was observed th
195 During the
median follow-up period of 4.1 years, the primary outcom
196 During a
median follow-up period of 4.2 years (range, 0-9 years),
197 of 326) experienced decompensation during a
median follow-up period of 4.22 years.
198 regular Z line developed HGD or EAC during a
median follow-up period of 4.8 years (interquartile rang
199 After a
median follow-up period of 58.2 months, 668 patients (50
200 (60%) no longer required opioid therapy at a
median follow-up period of 6 months.
201 Over a
median follow-up period of 6.5 years, we identified 2593
202 s (interquartile range 2.7-5 years), and the
median follow-up period was 3.75 years.
203 The
median follow-up period was 69 months (range, 6-126 mont
204 The
median follow-up periods were 28.4 and 27.4 mo for i-PET
205 At 17.2 months'
median follow-up,
the objective response rate was 23% (9
206 The
median follow-up time after cure was 11 months, during w
207 The
median follow-up time after random allocation was 10.3 y
208 Median follow-up time from transplantation to end of fol
209 During a
median follow-up time of 10.1 years (interquartile range
210 After a
median follow-up time of 11 months, the median overall s
211 PFS) and disease-specific mortality during a
median follow-up time of 18 months (range, 4-35 months).
212 At a
median follow-up time of 3 years (interquartile range, 2
213 ratio, 1.16; 95% CI, 0.97 to 1.38) during a
median follow-up time of 3.3 years.
214 mmol/l, 95%CI:0.26-0.74, p = 0.002) after a
median follow-up time of 33(21-36) months.
215 Results After a
median follow-up time of 35.7 months, 190 patients had d
216 l of 7542 recipients were followed up over a
median follow-up time of 5.3 years (interquartile range
217 le range, 35 to 58 years) at diagnosis and a
median follow-up time of 58 months (interquartile range,
218 matory drug (NSAID) users (n = 315).During a
median follow-up time of 59 mo, 200 participants (43.8%)
219 herapy, and no metastases were recorded in a
median follow-up time of 73.2 months (mean, 71.5; range,
220 still experienced wheat sensitivity after a
median follow-up time of 99 months.
221 The
median follow-up time to assess platelet responses was 1
222 Median follow-up time was 12.6 (to a maximum of 28.2) ye
223 The
median follow-up time was 15.5 y.
224 Median follow-up time was 16.8 months (range, 3.4-84.8 m
225 Median follow-up time was 2.4 (0.9-4.0) years.
226 The
median follow-up time was 4.8 years.
227 Median follow-up time was 6.7 years per recipient; total
228 Median follow-up time was 60 days for patients with comm
229 The
median follow-up time was 7.4 years (quartiles, 4.6-10.3
230 The
median follow-up time was 7.6 years (range, 0.1 to 10.1
231 The
median follow-up time was 82 months (range, 6-329 months
232 ponse was not reached in either cohort, with
median follow-up times of 12.8 months (IQR 9.3-15.5) in
233 Results
Median follow-up times were 15.0, 21.7, and 14.6 months
234 The
median follow up was 1.3 year (0-15.7).
235 Median follow up was 12.4 months (1.0-41.0).
236 ants and tested 130 seminal fluid specimens;
median follow up was 197 days (IQR 187-209 days) after e
237 Median follow up was 28.3 months (IQR 24.4-34.5) for the
238 Median follow-up was 1.7 months (IQR 1.4-4.1).
239 The
median follow-up was 10 months.
240 Median follow-up was 10.4 months (IQR 6.5-14.1) in the i
241 Median follow-up was 11.1 months (IQR 4.8-20.4).
242 Median follow-up was 11.1 months (IQR 5.1-18.0).
243 Median follow-up was 11.6 months (IQR 5.8-18.2) for the
244 Results At the time of the data snapshot,
median follow-up was 120 months.
245 At the time of analysis, the
median follow-up was 14 months (IQR 8-18) for all 91 pat
246 Median follow-up was 15.1 years and up to 25 years.
247 Median follow-up was 15.9 months (IQR 7.8-22.0) at the d
248 The
median follow-up was 16 wk (range, 2-30 wk).
249 Median follow-up was 16.2 years.
250 Median follow-up was 173 days (interquartile range: 54 t
251 Median follow-up was 18 (12-44) months.
252 Median follow-up was 18.2 years.
253 Median age at diagnosis was 12 years and
median follow-up was 2.3 years (interquartile range, 2.0
254 Median follow-up was 20.9 months (interquartile range, 8
255 Results The
median follow-up was 21.3 months.
256 The
median follow-up was 21.5 months (interquartile range, 1
257 Median follow-up was 23.2 months (IQR 14.8-28.7).
258 Median follow-up was 24 months (IQR 24-25).
259 Median follow-up was 24 months (range, 24-36 months).
260 The
median follow-up was 24.6 months.
261 The
median follow-up was 25 mo.
262 Median follow-up was 28.0 months (IQR 14.6-36.6).
263 At the time of the interim analysis, the
median follow-up was 29.4 months (range, 21.6 to 42.0).
264 Median follow-up was 29.5 months.
265 follow-up duration was up to 7.9 years, and
median follow-up was 3.1 years.
266 The
median follow-up was 3.7 years.
267 Median follow-up was 30 months (IQR 26-37).
268 The
median follow-up was 39.0 months (interquartile range, 5
269 The
median follow-up was 4 years for MFS and 3 years for non
270 lts Among 76 participants with WT-GISTs, the
median follow-up was 4.1 years.
271 Median follow-up was 4.7 (interquartile range, 2.4-8.1)
272 The
median follow-up was 40 months.
273 Median follow-up was 40 years (range 18-63).
274 Median follow-up was 428 days (range, 133-833) after the
275 Median follow-up was 43 months (interquartile range 35-4
276 Median follow-up was 43.3 months (IQR 31.6-58.4).
277 Median follow-up was 5 years 9 months.
278 Follow-up ended December 2013;
median follow-up was 5 years.
279 Median follow-up was 5.2 years (range, 0.2 to 9.5).
280 Median follow-up was 5.3 years (IQR 3.0-10.0, maximum 23
281 Median follow-up was 5.45 +/- 0.52 years.
282 Median follow-up was 50 months (IQR 41-54) for progressi
283 all, 125 patients met eligibility criteria;
median follow-up was 51 months for surviving patients.
284 The
median follow-up was 56.5 (95% CI, 54.5-59.2) months in
285 Median follow-up was 58 months (range 9-188).
286 Results
Median follow-up was 6.0 years.
287 The
median follow-up was 6.7 years, and the estimated 5- and
288 g per deciliter [1.8 mmol per liter] and the
median follow-up was 7 months), major cardiovascular eve
289 re recorded during follow-up across cohorts (
median follow-up was 7.4 years [IQR 5.7-8.9], range 2.0-
290 Median follow-up was 7.7 months (IQR 3.6-12.0) for patie
291 The
median follow-up was 707 days.
292 The
median follow-up was 8 years (range, 2 months to 23 year
293 Median follow-up was 8.2 years (mean, 9.7 years, 5452 ey
294 Median follow-up was 8.6 (range, 0.2-37) years.
295 At the time of analysis, the
median follow-up was 84 months (range, 1 to 119 months).
296 Median follow-up was 9.1 years (range 5.1 -21.2 yrs).
297 Median follow-up was 9.8 years (IQR 8.0-10.3).
298 The
median follow-up was 9.9 years.
299 Median age was 77 years (range 62-92), and
median follow-up was 953 days (IQR 721-1040).
300 age at transplantation was 9 years, and the
median follow-up was longer than 5 years.